RxDoctor Payments Data

Cathy Bowlin, NP

Nurse Practitioner · Corpus Christi, TXNPI 1316068414

Payments from drug & device makers

$2,000in general payments, 2019–2025

Across 109 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$442
  • Bayer$370
  • Novo Nordisk$350
  • AbbVie$316
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$122
  • AstraZeneca$75
  • plus $325 from 13 others

What the payments were for

  • Food & beverage$1,98799%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,000 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$2,537
Medicare patients
25
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$20,117
OzempicSemaglutide13$11,883
MyrbetriqMirabegron13$6,880
SymbicortBudesonide/Formoterol Fumarate11$2,402
Albuterol Sulfate HfaAlbuterol Sulfate37$898
Levothyroxine Sodium87$671
Gabapentin57$614
Atorvastatin Calcium65$427
Acetaminophen-CodeineAcetaminophen With Codeine22$394
Famotidine22$377
Pioglitazone Hcl17$286
Lisinopril52$267
Amlodipine Besylate45$241
Losartan Potassium26$224
Mirtazapine18$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$442$20,11715 claims
Novo NordiskOzempic$350$11,88313 claims
Astellas Pharma US IncMyrbetriq$16$6,88013 claims
AstraZenecaSymbicort$75$2,40211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →